Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
Rattachement africain : il, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Molnupiravir was granted emergency use authorization for the treatment of mild to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based real-world data to evaluate the effectiveness of molnupiravir. METHODS: The database of the largest healthcare provider in Israel was used to identify all adults with first-ever positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) performed in the community during January-February 2022, who were at high risk for severe COVID-19, and had no contraindications for molnupiravir use. Patients were included regardless of SARS-CoV-2 vaccination status. A total of 2661 patients who received molnupiravir were propensity score matched with 2661 patients who have not received molnupiravir (control group). Patients were followed through 10 March 2022 for up to 28 days for the first occurrence of the composite severe COVID-19 or COVID-19-specific mortality. RESULTS: The composite outcome occurred in 50 patients in the molnupiravir group and 60 patients in the control group. Molnupiravir was associated with a nonsignificant reduced risk of the composite outcome: hazard ratio, 0.83 (95% confidence interval, .57-1.21). However, subgroup analyses showed that molnupiravir was associated with a significant decrease in the risk of the composite outcome in older patients 0.54 (0.34-0.86), in females 0.41 (0.22-0.77), and in patients with inadequate COVID-19 vaccination 0.45 (0.25-0.82). The results were similar when each component of the composite outcome was examined separately. CONCLUSIONS: This study suggests that in the era of Omicron and in real-life setting, molnupiravir might be effective in reducing the risk of severe COVID-19 and COVID-19-related mortality, particularly in specific subgroups.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
- Date Crossref
- 20/09/2022
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Technion – Israel Institute of Technology pays non établi dans la noticeUniversité ou école supérieure
-
Carmel Medical Center Infection Control and Prevention Unit pays non établi dans la noticeÉtablissement de santé
-
Yale University pays non établi dans la noticeUniversité ou école supérieure
-
Emek Medical Center Internal Medicine C pays non établi dans la noticeÉtablissement de santé
-
Ruth and Bruce Rappaport Faculty of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Yale School of Medicine Critical Care and Sleep Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Translational Epidemiology Unit and Research Authority pays non établi dans la noticeOrganisme public
Technion – Israel Institute of Technology, Infection Control and Prevention Unit — Carmel Medical Center et Yale University, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.